About Neovasc (NASDAQ:NVCN)
Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company's segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: NASDAQ:NVCN
- CUSIP: N/A
- Web: www.neovasc.com
- Market Cap: $116 million
- Outstanding Shares: 78,910,000
- 50 Day Moving Avg: $1.52
- 200 Day Moving Avg: $1.40
- 52 Week Range: $0.46 - $3.34
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.35
- P/E Growth: 0.00
- Annual Revenue: $8.58 million
- Price / Sales: 13.52
- Book Value: ($0.35) per share
- Price / Book: -4.20
- EBITDA: ($23,140,000.00)
- Net Margins: -68.34%
- Return on Equity: -58.08%
- Return on Assets: 23.23%
- Current Ratio: 0.74%
- Quick Ratio: 0.74%
- Average Volume: 346,762 shs.
- Beta: 0.36
- Short Ratio: 20.57
Frequently Asked Questions for Neovasc (NASDAQ:NVCN)
What is Neovasc's stock symbol?
Neovasc trades on the NASDAQ under the ticker symbol "NVCN."
How were Neovasc's earnings last quarter?
Neovasc Inc. (NASDAQ:NVCN) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.02. The company earned $1.31 million during the quarter, compared to the consensus estimate of $1.40 million. Neovasc had a negative net margin of 68.34% and a negative return on equity of 58.08%. View Neovasc's Earnings History.
When will Neovasc make its next earnings announcement?
Where is Neovasc's stock going? Where will Neovasc's stock price be in 2017?
3 equities research analysts have issued 12-month target prices for Neovasc's stock. Their predictions range from $4.00 to $10.00. On average, they anticipate Neovasc's stock price to reach $6.33 in the next year. View Analyst Ratings for Neovasc.
Are investors shorting Neovasc?
Neovasc saw a decline in short interest in September. As of September 29th, there was short interest totalling 1,684,573 shares, a decline of 46.7% from the September 15th total of 3,160,903 shares. Based on an average daily volume of 433,922 shares, the short-interest ratio is presently 3.9 days. Currently, 5.0% of the shares of the stock are sold short.
Who are some of Neovasc's key competitors?
Some companies that are related to Neovasc include Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Harvard Bioscience (HBIO), IRIDEX Corporation (IRIX), Viveve Medical (VIVE), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Fulgent Genetic (FLGT), Electromed (ELMD), Biolase (BIOL), Invivo Therapeutics Holdings Corp (NVIV), Digirad Corporation (DRAD), Luna Innovations Incorporated (LUNA), Advanced Oncotherapy PLC (AVO), EnteroMedics (ETRM), Xtant Medical Holdings (XTNT) and Dynatronics Corporation (DYNT).
Who are Neovasc's key executives?
Neovasc's management team includes the folowing people:
- Paul L. Geyer, Independent Chairman of the Board
- Alexei J. Marko, Chief Executive Officer, Director
- Christopher Clark, Chief Financial Officer, Corporate Secretary
- Brian McPherson, Chief Operating Officer
- Vicki Lee Bebeau, Vice President - Clinical Affairs
- Randy Lane, Vice President - Research & Development
- Jane H. Hsiao Ph.D., Independent Director
- Douglas Glen Janzen, Independent Director
- William O'Neill, Independent Director
- Steven D. Rubin Esq. J.D., Independent Director
How do I buy Neovasc stock?
Shares of Neovasc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neovasc's stock price today?
MarketBeat Community Rating for Neovasc (NASDAQ NVCN)MarketBeat's community ratings are surveys of what our community members think about Neovasc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Neovasc stock can currently be purchased for approximately $1.47.
Earnings History for Neovasc (NASDAQ:NVCN)Earnings History by Quarter for Neovasc (NASDAQ NVCN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017|| || || || || || || || |
|8/10/2017||6/30/2017||($0.02)||($0.04)||$1.40 million||$1.31 million||View||N/A|
|11/14/2016||Q216||($0.06)||($0.12)||$2.20 million||$3.03 million||View||N/A|
|3/29/2016||Q415||($0.15)||($0.11)||$3.26 million||$2.24 million||View||N/A|
|11/9/2015||Q3 2015||($0.10)||($0.11)||$3.46 million||$2.48 million||View||N/A|
|8/6/2015||Q2 2015||($0.10)||($0.10)||$3.19 million||$2.93 million||View||N/A|
|5/12/2015||Q115||($0.05)||($0.08)||$3.84 million||$2.86 million||View||N/A|
|3/30/2015||Q414||($0.06)||($0.11)||$3.31 million||$3.35 million||View||N/A|
Earnings Estimates for Neovasc (NASDAQ:NVCN)
2017 EPS Consensus Estimate: ($0.12)
2018 EPS Consensus Estimate: ($0.04)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Neovasc (NASDAQ:NVCN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Neovasc (NASDAQ:NVCN)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Neovasc (NASDAQ:NVCN)
Latest Headlines for Neovasc (NASDAQ:NVCN)
Loading headlines, please wait.
Neovasc (NVCN) Chart for Sunday, October, 22, 2017